Announcement on the Submission of the Application of Manufacturing and Marketing Authorization for Allogeneic iPS Cell-Derived dopaminergic neural progenitor cells in Japan
Research and Development
2025.12.24
Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; “Sumitomo Pharma”) and RACTHERACo., Ltd. (Head Office: C…
